Albireo AB
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Nov 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Benzothia(DI)azepine Compounds and Their Use as Bile Acid Modulators (US 11,708,340) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due Feb 22, 2027The maintenance fee for Ibat Inhibitors for the Treatment of Liver Diseases (US 11,732,006) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 4 fees due Apr 3 to 30, 2027 · next Apr 3
- 1 fee due May 26, 2027The maintenance fee for Ibat Inhibitors for the Treatment of Liver Diseases (US 10,487,111) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Benzothia(di)azepine compounds and their use as bile acid modulators (US 11,891,368) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 1 fee due Oct 7, 2027The maintenance fee for Cholestyramine Pellets and Methods for Preparation Thereof (US 10,610,543) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,688,720 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 10,000,528 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 10,011,633 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 10,093,697 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 10,221,212 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 10,487,111 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 10,981,952 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 11,261,212 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 11,732,006 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence | |
| US 12,187,812 | Ibat Inhibitors for the Treatment of Liver Diseases In force · High confidence | In force | High confidence |
Also on record, not counted in the 50: 6 patents in force now held by others · 12 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
10 pending · 5 abandoned · 9 no status recorded